News & Press Releases

December 10, 2024, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on Vivos Therapeutics, Inc. (NASDAQ: VVOS) titled, “New Strategic Model & Key Regulatory Milestones Provide Revenue Tailwind.” The report can be accessed here.

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, including obstructive sleep apnea (“OSA”) in adults and children, reported that the American Medical Association (“AMA”) has issued new CPT(R)medical codes that are applicable to Vivos CARE oral medical devices; the codes are effective beginning Jan. 1, 2025.

Vivos Therapeutics shares are trading lower by 25% Thursday morning. The company announced a $4.3 million registered offering.

NVDA, TMUS, VVOS, SOFI, TSLA are the top trending stocks on Wednesday.

Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (“OSA”) in adults), has entered into definitive purchase agreements with institutional investors. Under these agreements, Vivos will issue and sell an aggregate of 1,363,812 shares of its common stock at a purchase price of $3.15 per unit in a registered direct offering.

The FDA has granted 510(k) clearance to Vivos Therapeutics' DNA oral appliance for treating moderate to severe obstructive sleep apnea and snoring in children aged 6-17.

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (“SRBDs”) including obstructive sleep apnea (“OSA”) has received breakthrough clearance from the U.S. Food and Drug Administration (“FDA”). According to the announcement, the company has received approval to use its Vivos proprietary oral medical device to treat moderate to severe OSA and snoring in children; the company believes this is the first time the FDA has given 510(k) clearance for this type of treatment for children aged 6 to 17 years of age.

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is reporting the financial results and operating highlights for its second quarter 2024 and six-month period, which ended June 30, 2024. Highlights of the report include a 19% increase in revenue both sequentially and year-over-year; a 31% decrease in operating expenses, marking eight consecutive quarters of improvement based on successful cost-cutting initiatives; and $6.9 million in cash and cash equivalents with stockholder equity totaling $6.3 million.

VVOS stock results show that Vivos Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (“OSA”) in adults), plans to release its second quarter 2024 financial results after market close today, Wednesday, August 14, 2024. In addition, the company’s management will host a conference at 5 p.m. ET to review the results and provide an overview of Vivos’ recent achievements and developments. Interested participants can dial (800) 717-1738 (local) or (646) 307-1865 (international) and use the passcode 1157721. A live webcast of the call can be accessed on the company’s website.

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is reporting on the positive results from seven-month pilot test. The multisite marketing initiative tested the core assumptions behind Vivos’ new affiliation and medical sleep specialist marketing and distribution model. Earlier this month, the company unveiled the new marketing and distribution model designed to drive revenue through collaborations with dentists and sleep-treatment providers. The pilot, which involved seven dental offices and one ear, nose, and throat specialist office located across several states with highly diverse patient demographic profiles, provided a way to offer obstructive sleep apnea (“OSA”) patients a range of evidence-based treatments for OSA. Included in the treatment options were Vivos’ advanced, proprietary and FDA-cleared CARE oral medical devices, oral appliances and additional adjunctive therapies and methods. According to the announcement, results indicated that 79% (60 out of 76) newly diagnosed adult OSA patients chose Vivos’ oral appliance therapy over either continuous positive airway pressure (“CPAP”) machines or doing nothing. The report also indicated that 5% (4 out of 76) of patients declined all treatment options with 16% (12 out of 76) patients chosing to investigate CPAP as an option before making a final decision. “We are excited about the positive results of this pilot program and what the data shows about the potential for our new marketing and distribution model,” said Vivos Therapeutics chair and CEO Kirk Huntsman in the press release. “The message is clear: when Vivos teams up with medical professionals who treat OSA, and when patients are fully informed as to the health risks of untreated OSA and the full range of treatment options available in an open and transparent manner, they overwhelmingly chose Vivos’ CARE oral medical devices. As we continue to expand beyond dentists and move more directly and vertically into affiliations and collaborations with medical specialists, functional medicine doctors, and other sleep-related healthcare practitioners, we expect this to positively impact our new case starts, revenue growth and gross profit.”

Vivos Therapeutics (NASDAQ: VVOS) is a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (“OSA”) in adults). The company today announced the execution of a strategic marketing and distribution alliance with an operator of multiple sleep testing and treatment centers in Colorado. Hoped to be the first in a series across the country, the alliance marks an important pivot in Vivos’ marketing and distribution model for its cutting edge OSA appliances. “We cannot overstate the importance of this alliance to Vivos and its future, coupled with a validating private equity-led investment from Seneca,” said Kirk Huntsman, chairman and CEO of Vivos. “Over the last several years, peer-reviewed studies have confirmed our longstanding belief that Vivos has the most effective, safe and potentially lasting non-surgical solution for all severities of OSA in adults that does not require lifelong nightly intervention. This was further validated by recent unprecedented FDA clearances Vivos has received, including the only FDA clearance for an oral medical device to treat severe OSA in adults.”

We are covering the biggest pre-market stock movers for Wednesday with all of the latest happenings worth watching this morning!

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is reporting financial results and operating highlights for the first quarter 2024, the period ended March 31, 2024. Highlights of the report include Q1 2024 revenue reaching $3.4 million; gross profit totaling $1.9 million; gross margin of 57%; a 22% decrease in operating expenses; and cash and cash equivalents totaling $2.6 million at the end of the quarter. The report noted that cost-cutting initiatives led to a significant year-over-year reduction in operating loss and an outstanding common stock purchase warrant held by an institutional investor was exercised for gross proceeds of approximately $4.0 million. In addition, last month the company received all required regulatory approvals to enable Medicare reimbursement for its CARE oral devices. “We are proud of the prudent way we have managed our costs and our cash resources as well as our successful efforts to expand our product offerings, gain unprecedented regulatory approvals and obtain Medicare reimbursement for our CARE oral devices,” said Vivos chair and CEO Kirk Huntsman in the press release. “That said, we recognize that our revenues have not grown as we would have liked. To that end, we are announcing today the anticipated launch of a new strategic revenue initiative based on collaborations to better align our interests with referring medical professionals, which we expect to materially broaden the number of OSA patients who have access to our products, make our revenue less reliant on VIP enrollments and build on the initiatives we’ve been implementing over the past year. We look forward to providing some additional details . . . in the coming weeks. All of these initiatives are intended to increase our ability to take advantage of what we see as steadily improving market conditions in OSA and open Vivos up for greater revenue opportunities. By doing this, we expect to position Vivos for long-term, sustainable revenue growth and ultimate profitability.”

Vivos Therapeutics just reported results for the first quarter of 2024.

Vivos Therapeutics (NASDAQ: VVOS) is a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (“OSA”) in adults). The company today announced plans to release its first quarter 2024 financial results after market close on Tuesday, May 14, 2024. On this same day, the company will conduct a conference call at 5:00 p.m. Eastern Time to review the results and provide an overview of its recent milestones and developments. To access Vivos’ investor conference call, dial (800) 717-1738 or (646) 307-1865 (international callers). A replay and live and archived webcast of the conference call will be available as detailed in the announcement.

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, is spotlighted in a recent Proactive interview. During the interview, Vivos CEO Kirk Huntsman and Proactive host Steve Darling discuss the latest news from the company, which is the regulatory approval for Medicare reimbursement of oral medical devices designed for sleep apnea treatment. Huntsman explains the unique design of the company’s medical devices, which enhance the human airway and have the potential to eliminate sleep apnea symptoms after up to 12 months of treatment. Huntsman also notes that Vivos offers the only line of oral medical devices that has received FDA approval for the treatment of obstructive sleep apnea (“OSA”). This is a significant achievement because some tens of millions of Medicare patients who suffer from OSA stand to benefit from the Vivos devices. “This recognition by the Centers for Medicare and Medicaid Services (‘CMS’) propels Vivos’s devices as a viable alternative to traditional CPAP treatments, especially timely given the recent recalls in the CPAP market and Philips’ withdrawal from the U.S. market,” the press release states. “Huntsman expressed his excitement about the broader implications of this approval, including increased recommendations of Vivos’s treatments by medical and dental providers and a growing awareness of their efficacy as an alternative to CPAP treatments. This development represents a significant step forward in transforming patient care for individuals suffering from sleep apnea.”

Vivos Therapeutics shares are trading lower Tuesday. The company filed a prospectus related to the resale of up to 1.73 million shares of common stock by selling shareholders. Vivos said that if the warrants held by the selling stockholder are exercised in full for cash, the company would receive approximately $8.4 million.